Opendata, web and dolomites

CL-IO SIGNED

Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CL-IO project word cloud

Explore the words cloud of the CL-IO project. It provides you a very rough idea of what is the project "CL-IO" about.

sought    tumour    minority    release    colonise    trimodal    l19    rates    despite    urgency    checkpoint    io    genetically    tumours    cellular    business    inclusion    technological    factories    immunotherapeutic    weapons    hypoximmuno    therapy    accelerator    limitation    prepare    strategy    immunotherapy    cancers    mortality    modality    immunotherapeutics    antibody    patients    combating    necrosis    poc    powerful    position    agents    dictated    strategic    vimeo    watch    lung    necrotic    malignancies    bacteria    act    break    benefit    delivering    lambin    start    positioning    escape    erc    cancer    routes    radiotherapy    hypoxic    incidence    strategies    tumors    ip    optimal    hypoxia    https    stereotactic    mechanisms    clostridium    com    market    il2    team    prof    251022032    off    precision    feasibility    gain    model    site    immunotherapies    suppression    overcome    proof    producing    therapeutic    14    innovative    experts    exact    first    immune    commercial    commercialisation    inhibitor    proven    limited    immunocytokine    respect    solid    push    modified    spin    worldwide    selectively    cl    regions   

Project "CL-IO" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙802 €
 EC max contribution 150˙000 € (99%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 150˙000.00

Map

 Project objective

Immunotherapeutic strategies are powerful weapons in combating malignancies. However, only a minority of patients benefit from this therapeutic modality, as tumours develop mechanisms of immune escape and suppression and uptake of (antibody-based) agents in tumors is limited. The urgency of investigating novel strategic approaches is dictated by the high incidence and mortality rates of cancer worldwide. Lung cancer, in particular, is the leading cancer with respect to incidence and mortality (14% of new cancers). In the ERC Advanced “HYPOXIMMUNO”, Prof. Lambin and his team have investigated the trimodal therapy involving high precision Stereotactic Radiotherapy, hypoxia/necrosis targeting and tumour specific immunotherapy (immunocytokine L19-IL2 to “push the accelerator” with a checkpoint inhibitor to “release the break”). Despite promising results, the delivery of immunotherapeutics to the tumour site has proven to be challenging. Prof. Lambin and his team have sought to overcome this limitation with the inclusion of genetically-modified Clostridium bacteria as optimal delivery system capable of effectively delivering immunotherapeutics within the tumour. These Clostridium-bacteria selectively colonise the hypoxic/necrotic regions present in solid tumours and act as cellular factories capable of continuously producing tumour-specific immunotherapies within the tumour (watch https://vimeo.com/251022032 ). In this ERC PoC project, a team of technological and commercial experts will investigate the commercial feasibility of this innovative approach. We will prepare the first steps towards the start-up of a spin-off, by defining the exact business strategy, model and positioning for commercial success. We will develop the business strategy based on the technological aspects, the market needs and trends, and the IP-position. During CL-IO, we will gain technical and commercial proof-of-concept, providing the necessary information for potential commercialisation routes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CL-IO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CL-IO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More